One to Watch: Have (MDCX) Up On Your Screen Early Tomorrow Morning

Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Medicus Pharma Ltd.

Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.

See Why (MDCX) Just Hit Our Radar And Will Be Topping Tomorrow Morning’s Watchlist —Wednesday, April 15, 2026

April 14, 2026

Dear Reader,

Recent news involving Medicus Pharma Ltd. (NASDAQ: MDCX) — and it's shaping up to be a story worth following.

The company just revealed it submitted an optimized Phase 2 protocol to the U.S. FDA for Teverelix® in acute urinary retention, according to the April 6 press release — going after a $2B market with no approved pharmacologic therapies on the board.

Think about that. A biotech under $20M market cap just stepped into a lane with zero competition.

Here's why we're putting a spotlight on (MDCX) tomorrow morning.

According to Grand View Research, the global Basal Cell Carcinoma treatment market is on track to reach $5.93B by 2030. Right in the middle of this growing space sits a company building out two potentially game-changing therapeutics.

Medicus Pharma Ltd. (NASDAQ: MDCX) is topping our watchlist tomorrow morning— Wednesday, April 15, 2026.

According to Yahoo Finance, (MDCX) carries just 32.82M shares in its public float—with a float that small, the potential exists for big moves if demand begins to shift.

Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $6 target on (MDCX) which suggests 1,400% upside potential from its recent $.40 range.

Who Is Medicus Pharma?

Medicus Pharma is a precision-focused biotech pushing forward novel therapeutics in oncology and urology. Its flagship, SkinJect™, is a patented dissolvable microneedle array delivering doxorubicin locally for non-invasive BCC treatment through a 505(b)(2) pathway.

The second asset, Teverelix®, is a next-generation GnRH antagonist built for advanced prostate cancer and acute urinary retention recurrence.

This is where things heat up — both programs are reaching critical inflection points at once.

Recent Pipeline Developments

Teverelix® Phase 2 Filed with the FDA: Per the April 6 release, the trial targets ~126 patients across the U.S. and Europe with an interim readout at ~50% enrollment.
SkinJect™ Phase 2 — ~80% Overall Response Rate: Per the April 1 release, the 200-µg cohort showed 73% clinical clearance and 40% histological clearance. KOL Dr. Babar Rao independently validated the data.
EOP2 FDA Meeting Approaching: Targeting first half of 2026 for SkinJect™ — a pivotal registrational milestone.
Reliant AI Partnership: Medicus teamed up with Reliant AI Inc. for agentic AI-driven clinical analytics, per the March 26 update.
National Media Push: A 12-part New to The Street series kicked off in April 2026 on Bloomberg TV and FOX Business.

Now step back and look at the bigger picture — the macro backdrop lines up with these potential catalysts.

Where the Market Is Headed

Grand View Research projects intralesional injections as the fastest-growing segment through 2030 — mapping directly onto SkinJect™'s delivery model. The addressable pipeline per the March 26 update:

SkinJect™: ~$2B for non-melanoma skin cancers including Gorlin Syndrome
Teverelix® (AURr): ~$6B with zero approved pharmacologic competition
Combined Pipeline: ~$8B total addressable market

Let's put it all together — here's exactly why (MDCX) landed on our radar.

4 Reasons Why (MDCX) Will Be Topping Our Watchlist Tomorrow Morning…

1. Limited Share Availability: Only 32.82M shares per Yahoo Finance and a ~$16M market cap per Yahoo Finance — momentum builds fast with this setup.

2. Back-to-Back Potential catalysts: An ~80% ORR from SkinJect™, a freshly submitted Teverelix® protocol, and an EOP2 FDA meeting — all converging this quarter. The Teverelix® study was shaped by Dr. Steven A. Kaplan, a world-renowned BPH authority from Mount Sinai.

3. Wide-Open Market + Growing Visibility: Teverelix® targets AURr with zero approved competition, and the New to The Street campaign on Bloomberg TV and FOX Business may drive awareness at just the right time.

4. Analyst Coverage: Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $6 target on (MDCX) which suggests 1,400% upside potential from its recent $.40 range.

Pull Up (MDCX) Before The Morning Gets Here...

A 32.82M share float, ~80% Phase 2 response rate, a fresh FDA protocol aimed at $2B uncontested, and ~$8B in combined addressable pipeline — could (MDCX) be gearing up for a turnaround from here?

We will have all eyes on (MDCX) tomorrow, Wednesday, April 15, 2026.

Sincerely,

Dean Knightly
Editor, Trading Ideas

^{TradingIdeas.app}^{(“TradingIdeas” or “TI” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and TI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile TI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

^{Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC one hundred thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid one million forty thousand USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither TD Media LLC and their member own shares of (MDCX:US).}

^{Please see important disclosure information here:}^{https://tradingideas.app/disclosure/mdcx-7E33I/#details}